We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Benign Hematology

Journal Scan / Research · May 23, 2022

Prognostic Significance of ASXL1 Mutations in Primary Myelofibrosis Following Essential Thrombocythemia or Polycythemia Vera

Blood Advances


Additional Info

Blood Advances
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera
Blood Adv 2022 May 10;6(9)2927-2931, P Guglielmelli, G Coltro, F Mannelli, G Rotunno, GG Loscocco, C Mannarelli, C Maccari, C Paoli, S Romagnoli, N Bartalucci, AM Vannucchi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading